Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Human Genome Shares Rise on Lupus Drug Study Data

By Pharmaceutical Processing | June 11, 2009

NEW YORK (AP) — Shares of Human Genome Sciences Inc. jumped Thursday after the company said its drug candidate Benlysta reduced lupus symptoms over a four-year period in a study. The stock jumped 59 cents, or 21.7 percent, to $3.30 in afternoon trading. Shares have traded between 45 cents and $8 over the last 52 weeks. The extended clinical trial showed that Benlysta patients experienced less severe flare-ups from the inflammatory disease and overall, those flare-ups decreased. The long-term study results come ahead of expected late-stage clinical trial data in July. Results from a second late-stage study are expected in November. “This (study) data makes us incrementally more positive on the upcoming pivotal Phase III BLISS-52 (study) data expected next month,” wrote Leerink Swann Research analyst Joseph P. Schwartz in a note to investors. He maintained an “Outperform” rating on the stock. Benlysta was previously called LymphoStat-B, and is being developed through a partnership between Rockville, Md.-based Human Genome Sciences and British drug maker GlaxoSmithKline PLC.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE